| Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome. | |
| | |
MedLine Citation:
|
PMID: 21167503 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Susac's syndrome is the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss (Susac 1994) [1]. It occurs predominantly in young females and is believed to be an immune-mediated endotheliopathy of small vessels of the brain, retina and cochlea (Neumayer et al. 2009) [2]. Early, aggressive, and sustained immunosuppressive therapy has been recommended for Susac's syndrome and anecdotal evidence has suggested a therapeutic role for monoclonal antibodies (Rennebohm et al. 2008, Lee and Amezcua 2009) [3,4]. We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab. |
| | |
Authors:
|
T A Hardy; R J Garsia; G M Halmagyi; S J G Lewis; B Harrisberg; M J Fulham; M H Barnett |
Related Documents
:
|
16117243 - Haddad syndrome: a case study. 1149323 - Congenital ichthyosis, mental retardation, dwarfism and renal impairment: a new syndrome. 16963483 - Development of a genotyping microarray for usher syndrome. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-12-17 |
Journal Detail:
|
Title: Journal of the neurological sciences Volume: 302 ISSN: 1878-5883 ISO Abbreviation: J. Neurol. Sci. Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-02-14 Completed Date: 2011-05-27 Revised Date: 2012-03-16 |
Medline Journal Info:
|
Nlm Unique ID: 0375403 Medline TA: J Neurol Sci Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 126-8 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
Department of Neurology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia. thardy@med.usyd.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use Antibodies, Monoclonal / therapeutic use* Azathioprine / therapeutic use Brain / pathology Cognition Disorders / etiology, psychology Cyclophosphamide / therapeutic use Epilepsy, Generalized / etiology Female Humans Immunoglobulins, Intravenous / therapeutic use Immunosuppressive Agents / therapeutic use Magnetic Resonance Imaging Neuropsychological Tests Prednisone / therapeutic use Reverse Transcriptase Polymerase Chain Reaction Seizures / etiology Susac Syndrome / drug therapy*, psychology Tumor Necrosis Factor-alpha / antagonists & inhibitors* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Immunoglobulins, Intravenous; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 446-86-6/Azathioprine; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone |
| Comments/Corrections | |
Comment In:
|
J Neurol Sci. 2012 Mar 15;314(1-2):181-2; author reply 183
[PMID:
22178082
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism.
Next Document: Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis ...